Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial.

导出 LinkOut

翻译打印收藏纠错

作者： Frida Bugge,Askeland ^[1] ; Einar,Haukås ^[2] ; Tobias S,Slørdahl ^[3] ; Anja,Klostergaard ^[4] ; Tatjana,Alexandersen ^[5] ; Anna,Lysén ^[5] ; Pegah,Abdollahi ^[5] ; Lene Kongsgaard,Nielsen ^[6] ; Emil,Hermansen ^[7] ; Fredrik,Schjesvold ^[5]

作者单位： Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Electronic address: friask@ous-hf.no. ^[1] Department of Cancer and Blood Diseases, Stavanger University Hospital, Stavanger, Norway. ^[2] Department of Hematology, St Olavs Hospital, Trondheim, Norway; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway. ^[3] Department of Hematology, Aarhus University Hospital, Aarhus, Denmark. ^[4] Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway. ^[5] Quality of life Research Center Department of Hematology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Section of Haematology, Department of Internal Medicine, Gødstrup Hospital, Herning, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. ^[6] Department of Hematology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. ^[7]

主题词人类(Humans);多发性骨髓瘤(Multiple Myeloma);地塞米松(Dexamethasone);女(雌)性(Female);男(雄)性(Male);老年人(Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);中年人(Middle Aged);老年人, 80以上(Aged, 80 and over);治疗结果(Treatment Outcome)

DOI 10.1016/S2352-3026(24)00347-8

PMID 39909655

发布时间 2025-02-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

The Lancet. Haematology

2025年12卷2期

e120-e127页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial.

The Lancet. Haematology

相似文献

The Lancet. Haematology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial.

The Lancet. Haematology

相似文献

The Lancet. Haematology

相关期刊

检索历史清除